Tucatinib Together With Pembrolizumab and Trastuzumab
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to HER2-positive Breast Cancer
Related studies linked through entity extraction aliases.
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
- Status
- UNKNOWN
- Phase
- PHASE2
18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
- Status
- COMPLETED
- Phase
- N/A
De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade
- Status
- TERMINATED
- Phase
- PHASE2
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
- Status
- SUSPENDED
- Phase
- PHASE1
Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis
- Status
- UNKNOWN
- Phase
- PHASE2
Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer
- Status
- RECRUITING
- Phase
- N/A
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC
- Status
- UNKNOWN
- Phase
- N/A
Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy
- Status
- TERMINATED
- Phase
- PHASE2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2